Oncology biotech with quite an extensive pipeline of products under development in renal, brain, prostate and other cancers. Aiming for FDA approval in around September. Very impressive management. Has been hitting resistance around 4.70/$4.80 but broke through convincingly on Friday. Not so confident about getting 25% in 4 weeks, given the size of the company, but that breakout was impressive.
